The Firm represented Microsoft Corporation in connection with its offering of $10.75 billion aggregate principal amount of senior notes. More >>

Simpson Thacher represented the underwriters, led by Goldman, Sachs & Co. and Deutsche Bank Securities Inc., in connection with the registered public offering by Apple Inc. of $6.5 billion aggregate principal amount of notes over five tranches with maturities ranging from 5 to 30 years. The net proceeds from the offering will be used for general corporate purposes, including repurchases of common stock and payment of dividends under Apple’s recently expanded program to return capital to shareholders, funding for working capital, capital expenditures and acquisitions and repayment of debt. More >>

A team of leading intellectual property lawyers has joined Kaye Scholer LLP in the firm’s Silicon Valley office, bringing to the firm extensive patent litigation experience in the Life Sciences and Technology industries. The group is led by Deborah Fishman, who joins as a partner, and includes Krista Carter and Katie Scott, who join as counsel. More >>

The Firm recently represented the initial purchasers, led by Goldman, Sachs & Co., Morgan Stanley and Credit Suisse, in connection with Micron Technology, Inc.’s offering of $1.0 billion aggregate principal amount of 5.25% Senior Notes due 2023. The notes were offered in reliance on Rule 144A and Regulation S under the Securities Act of 1933, as amended. More >>

Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, and NUCYNTA® (tapentadol), an immediate release version of tapentadol. The deal will make NUCYNTA the flagship asset in Depomed’s growing portfolio of pain and neurology specialty pharmaceuticals. More >>